Market Overview

UPDATE: Citigroup Initiates Coverage on Teva Pharmaceutical Industries Ltd. on Attractive Risk-Reward Profile

Related TEVA
Teva Launches Generic Avodart Capsules in the US
Don't Worry Spec. Pharma Investors, Drug Pricing Legislation Probably Won't Affect You
Teva launches Avodart generic in U.S. (Seeking Alpha)

In a report published Friday, Citigroup analyst Liav Abraham initiated coverage on Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) with a Buy rating and $47.00 price target.

In the report, Citigroup noted, “We see the potential for value to be unlocked over the next 12 months as investors look past the Copaxone cliff, and focus on the growth profile of the company's ex-Copaxone franchises, which comprise c.80% of the company's intrinsic value and are growing at a 19% 5-year CAGR. We also see the potential for material upside from potential shareholder-friendly actions on the part of management. Actavis and Teva are our Buy-rated names within the multinational generic universe.”

Teva Pharmaceutical Industries Ltd. closed on Thursday at $40.32.

Latest Ratings for TEVA

Sep 2015NomuraInitiates Coverage onNeutral
Aug 2015Goldman SachsReinstatesBuy
Aug 2015JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamAnalyst Color Initiation Analyst Ratings


Related Articles (TEVA)

Get Benzinga's Newsletters